After activation by its ligands, GPR109A can significantly inhibit the body’s inflammatory response in different diseases such as atherosclerosis, obesity, sepsis, diabetes, colitis, and neurodegenerative diseases (10). This evidence concerns the gene HCAR2 and colitis.